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Abstract Renal amyloidosis is a detrimental disease
caused by the deposition of amyloid fibrils. A child with
renal amyloidosis may present with proteinuria or nephrotic
syndrome. Chronic renal failure may follow. Amyloid
fibrils may deposit in other organs as well. The diagnosis
is through the typical appearance on histopathology.
Although chronic infections and chronic inflammatory
diseases used to be the causes of secondary amyloidosis
in children, the most frequent cause is now autoinflamma-
tory diseases. Among this group of diseases, the most
frequent one throughout the world is familial Mediterranean
fever (FMF). FMF is typically characterized by attacks of
clinical inflammation in the form of fever and serositis and
high acute-phase reactants. Persisting inflammation in
inadequately treated disease is associated with the
development of secondary amyloidosis. The main treat-
ment is colchicine. A number of other monogenic
autoinflammatory diseases have also been identified.
Among them cryopyrin-associated periodic syndrome
(CAPS) is outstanding with its clinical features and the
predilection to develop secondary amyloidosis in untreat-
ed cases. The treatment of secondary amyloidosis mainly
depends on the treatment of the disease. However, a
number of new treatments for amyloid per se are in the
pipeline.
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Introduction
The amyloidoses constitute a group of diseases characterized
by extracellular tissue deposition of fibrils composed of low-
molecular-weight subunits of a variety of proteins [1–3]. All
amyloid fibrils appear faintly red on Congo red staining on
microscopic examination and show a typical apple-green
birefringence under polarized light. The site of deposition
relies on the type of amyloidosis, which can be acquired or
hereditary, localized or systemic. At least 25 different
precursors of amyloid fibrils are now known; the main protein
types leading to amyloidosis are shown in Table 1 [1–3].
In pediatrics, the most common form of amyloidosis is
reactive AA amyloidosis duetochronic inflammatory diseases.
AA amyloidosis secondary to chronic infectious diseases was
common in the early 20th century. However, due to the
advances in the management of chronic infections such as
tuberculosis, this is no longer the case. Juvenile idiopathic
arthritis (JIA) was also a cause of secondary amyloidosis,
however, with better recognition and treatment, as well as the
introduction of biologics, secondary amyloidosis rarely occurs
in JIA in this decade. The main cause of childhood amyloidosis
is familial Mediterranean fever (FMF) and the other auto-
inflammatory diseases. AL amyloidosis, which is generally
seen in the elderly, is the most common type of amyloidosis in
the developed countries today. β2-microglobulin amyloidosis
(Aβ2M amyloidosis) is seen in patients with renal failure.
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dominant, and late-onset diseases having rarely been reported
in children [1–3].
This review discusses the pathogenesis, common causes
such as autoinflammatory diseases with special emphasis
on FMF, clinical manifestations, diagnosis, and treatment of
amyloidosis.
Pathogenesis
The production of precursor proteins, deposition of amyloid
fibrils, and tissue/organ damage are the three major steps in
the pathogenesis of amyloidosis. The nature of the
precursor protein yields the main component of amyloid
fibrils and the propensity for forming amyloid is related to
the characteristics of this precursor protein. The amyloido-
genic potential of precursor proteins is mainly affected by
three factors: overproduction, decreased clearance, and their
stability [1–7].
Overproduction
The production of precursor proteins are increased in
several conditions such as chronic inflammatory diseases
(AA amyloidosis) and immunoglobulin light chain amy-
loidosis (AL amyloidosis) [2, 4]. The precursor of amyloid
A protein is serum amyloid A (SAA), an acute phase
protein produced in response to inflammation [8, 9]. Serum
amyloid A is produced by inflammatory signals, interleukin
(IL)-1β, tumor necrosis factor (TNF)-α, and IL-6. Poly-
merization of SAA into amyloid fibrils requires removal of
the C-terminal of the AA protein [10]. The persistent
augmentation of an inflammatory pathway through the
innate immune system might be crucial in the deposition of
the amyloid protein leading to the clinical picture of renal
amyloidosis [8].
Decreased clearance
In healthy individuals, β2-microglobulin is synthesized at a
constant rate, but retention of it occurs in renal failure. In
the case of amyloidosis associated with β2-microglobulin,
the clearance of β2-microglobulin is decreased and plasma
levels can be elevated as much as 60-fold [5].
Unstable proteins
Genetically transmitted mutations make unstable proteins
prone to fibril conversion. Transthyretin [TTR], apolipo-
protein A [apoA]-I, apoA-II, fibrinogen, gelsolin, cystatin C
and lysozyme are examples of mutated proteins associated
with hereditary amyloidosis [3, 7].
Clinical manifestations due to amyloidosis
Amyloidosis is a multisystemic disease. Therefore, the
clinical manifestations due to amyloidosis vary widely and
depend on the involved organ(s) and the amount of amyloid
fibrils deposited. Symptoms and findings due to amyloid
deposition may be accompanied by the clinical manifesta-
tions of the underlying disease. Amyloid fibrils are most
commonly deposited in the kidneys, but may also attack the
heart, peripheral nerves, thyroid, gastrointestinal system, and
bone marrow. The organs involved are affected by the type of
amyloidfibrils.Clinically, itisdifficulttodistinguishAA and
AL amyloidosis from each other because of overlapping
clinical presentations. Although more than one organ is
generally affected, localized forms can occur as well.
Involvement of heart and kidneys are the most important
predictors affecting survival. On the other hand, gastrointes-
tinal amyloidosis may also have devastating complications
[1, 3, 9]. In secondary amyloidosis, kidney is the most
affected organ, the others are rarely involved.
Table 1 Important amyloid fibrils for nephrologists
Amyloid protein Precursor protein Clinical syndrome
AA Serum amyloid A protein Secondary, reactive, associated with chronic inflammatory diseases
AL Monoclonal Ig light chains Primary, associated with monoclonal plasma cell dyscrasias
AH Monoclonal Ig light chains Primary, associated with monoclonal plasma cell dyscrasias
Aβ2M β2-microglobulin Associated with dialysis
AFib Fibrinogen α-chain Familial autosomal dominant systemic amyloidosis
ACys Cystatin C Hereditary cerebral hemorrhage with cerebral and systemic amyloidosis
ALys Lysozyme Familial autosomal dominant systemic amyloidosis
AApoAI Apolipoprotein AI Familial
AApoAII Apolipoprotein AII Familial
ATTR Transthyretin Familial
AGel Gelsolin Familial
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Asymptomatic proteinuria is the most common initial
presentation of kidney disease. Thus, urinalysis should be
routinely examined in patients with a disease associated
with the risk of secondary amyloidosis. The most common
and earliest sign of amyloidosis in FMF is proteinuria,
gradually progressing to nephrotic syndrome and/or renal
dysfunction. In the series reported by the Turkish FMF
study group, the presenting clinical features of the patients
with amyloidosis secondary to FMF were as follows: 32%
proteinuria, 40% nephrotic syndrome, and 28% chronic
renal failure [11]. Hematuria and hypertension almost never
occurs [8]. Edema can exist in nephrotic patients [12].
The amount of proteinuria and renal function vary in
each case, which is related to the amount and/or site of
amyloid deposition. Uda et al. [13] demonstrated that
patients having glomerular amyloid deposition are more
common and have a poorer prognosis than patients having
vascular and tubular amyloid deposition in rheumatoid
arthritis-related AA amyloidosis. Nishi et al. [14] showed
that 10–30% of patients with renal amyloidosis might have
only mild proteinuria and normal renal function. Some
patients present with renal failure with little or no
proteinuria due to primary deposition of amyloid fibrils to
blood vessels or tubules. Signs of tubular dysfunction such
as type 1 (distal) renal tubular acidosis, nephrogenic
diabetes insipidus related polyuria, [15] and acquired
Fanconi syndrome [16] have been rarely reported as well.
Heart
Systolic or diastolic dysfunction, and arrhythmia are the
main presenting features of heart involvement. Cardiac
involvement is more rare in AA amyloidosis compared to
AL amyloidosis [17–19] and may progress rapidly.
Gastrointestinal tract
The gastrointestinal system is one of the common affected
sites in systemic amyloidosis. Since the rectum is com-
monly affected and easily reachable, rectal biopsy is the
initial diagnostic tool used in most of the cases. Gastroin-
testinal presentations are frequently nonspecific and may
include dyspepsia, abdominal pain, nausea, diarrhea,
gastrointestinal bleeding, malabsorption, constipation, and
obstruction [20, 21]. Acute gastrointestinal system symp-
toms may resemble FMF attacks.
Liver and spleen
The deposition of amyloid fibrils in liver and spleen leads
to hepatomegaly and splenomegaly [22–24]. Serum liver
enzymes can elevate, which makes prescription of drugs
difficult. Splenomegaly can cause hypersplenism and rarely
splenic rupture [25, 26].
Hematopoietic system
Amyloid fibrils can accumulate in the bone marrow [27].
Amyloidosis can cause bleeding diathesis due to factor X
deficiency, liver disease, or infiltration of blood vessels
[28]. Thrombotic events due to underlying disease, ne-
phrotic syndrome, and amyloidosis can also be seen [29].
Nervous system
Mixed sensory and motor peripheral neuropathy and
autonomic neuropathy may occur in amyloidosis albeit rare
in the secondary forms. Neuropathy is a prominent feature
in some of the hereditary amyloidoses (called familial
amyloidotic polyneuropathy) [30]. Central nervous system
involvement is unusual in patients with AA amyloidosis.
Miscellaneous
Infiltration of amyloid fibrils may cause enlargement of
muscles and arthropathy. The clinical manifestations of
Aβ2M amyloidosis include carpal tunnel syndrome, bone
cysts, spondyloarthropathy, pathologic fractures, and swol-
len painful joints [5]. Deposition of amyloid fibrils in
endocrine glands can affect organ function causing adrenal
insufficiency, hypothyroidism, and hypogonadism [31].
Symptoms related to the respiratory system and skin have
also been reported.
Diagnosis
Suspicion is essential in subjects having an underlying
disease with a potential to cause amyloidosis. Amyloidosis
should be suspected typically in a patient who presents with
proteinuria and who has one of the autoinflammatory
syndromes. However, organs other than the kidney may
be affected as well. In fact, in patients who are candidates
for this complication, secondary amyloidosis should also be
considered in the differential diagnosis of cardiomyopathy,
peripheral neuropathy, hepatomegaly, or in the presence of
symptoms related to the gastrointestinal tract.
The diagnosis of amyloidosis is based on the demon-
stration of amyloid fibrils in the biopsy of the involved
tissue (Fig. 1). In addition to renal biopsy, rectal or
abdominal fat biopsies may also reveal amyloid deposition.
Although renal, rectal, or abdominal biopsies are common-
ly used, tissues obtained by any diagnostic intervention or
surgical procedure may yield the diagnosis: for example a
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endoscopy done for vomiting, intestinal biopsy done for
malabsorption, pleural biopsy done for pleural effusion,
lung biopsy done for restrictive lung disease, bone marrow
biopsy done for anemia, excision of a local mass or surgery
for carpal tunnel syndrome can reveal amyloidosis [2, 3, 9].
The deposited amyloid fibrils are extracellular, eosino-
philic, and metachromatic on light microscopy. Congo red
staining is necessary for diagnosis. Amyloid fibrils appear
faintly red on Congo red staining and show the characteristic
apple-green birefringence under polarized light. Specific
investigation is needed for detection of the types of amyloid
fibrils. Immunofluorescence or immunohistochemical stain-
ing of the tissue using antibodies that are directed against
known amyloidogenic proteins are easy, common, and
inexpensive methods of typing amyloid fibrils. Immunoelec-
tron microscopy, Western blotting, mass spectrometry, and
amino acid sequencing are methods that can be used in the
typing of amyloid deposits [32, 33].
Actually, infiltrative renal diseases including amyloidosis
must be considered in the differential diagnosis of all patients
having chronic kidney disease and normal or large sized
kidneys. AA amyloidosis can also be diagnosed using serum
amyloid P component scintigraphy [34].
Reporting of renal biopsies The histopathologic changes
comprise a spectrum in renal amyloidosis. Clear relationships
between the extent of amyloid deposition and the severity of
clinical manifestations have not been demonstrated. The
studies investigating clinico-pathologic correlations face
some difficulties due to the absence of standardization of the
relevant biopsy reports. This issue was discussed at several
meetings [32, 33] and Sen and Sarsik proposed a histopath-
ologic classification, scoring, and grading system aiming to
standardize the biopsy reports of renal amyloidosis [33].
They divided glomerular amyloid deposition into six classes,
similar to the classification of systemic lupus erythematosus.
Amyloid depositions (glomerular, vascular, and interstitial)
and other histopathologic lesions such as interstitial fibrosis,
atrophy, inflammation, and glomerular sclerosis were scored.
The sum of these scores was termed the renal amyloid
prognostic score and was divided into three grades: early,
late, or advanced. Ninety percent of the investigated cases
had AA amyloidosis mostly related to FMF. Because of the
inadequacy of the patients’ records and outcomes, different
therapy regimes, and etiologies, clinical validation of this
study has not been completed, but this histopathologic
classification, scoring, and grading system is promising for
further research.
Underlying causes of secondary amyloidosis
Juvenile idiopathic arthritis
Juvenile idiopathic arthritis is the most common rheumatic
disease of childhood. The diagnostic criteria require a child
of less than 16 years of age with arthritis for at least
Fig. 1 Typical apple-green birefringence under polarized light, Congo
redstaining:a kidney (×200), b skin (×200), and c thyroid gland (×400)
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causes of arthritis. Juvenile idiopathic arthritis has been
classified into seven subtypes [35]. Secondary amyloidosis
used to be one of the most serious and fatal complications
of JIA. Before the 1990s, the incidence of secondary
amyloidosis was as high as 2.1%, with lower rates in North
America. The form of JIA is important; amyloidosis has
been observed mainly in systemic and polyarticular forms
[36]. Secondary amyloidosis due to JIA has been decreas-
ing dramatically in recent years, which is due to earlier
recognition and better management of the disease and the
introduction of new biologic agents. In this decade,
amyloidosis is a rare entity in JIA.
Autoinflammatory syndromes
Autoinflammatory syndromes are defined as a group of
diseases characterized by unprovoked inflammatory episodes
and the lack of autoantibodies [37]. Most of the well-defined
diseases in this group are monogenic diseases. The spectrum
of autoinflammatory diseases has now expanded from the
monogenic diseases such as FMF and TNF-receptor-
associated periodic fever syndrome (TRAPS) to the more
common polygenic diseases such as Behçet’s disease,
Crohn’s disease, and others [38]. The subject of auto-
inflammatory diseases has become an exciting and growing
but debatable one; it will be a difficult challenge to precisely
classify inflammatory diseases in the spectrum of auto-
inflammation to autoimmunity.
Familial Mediterranean fever
Familial Mediterranean fever (FMF) is an autoinflamma-
tory disease characterized by recurrent attacks of fever and
serositis. FMF is of interest to nephrologists for a number
of reasons:
– FMF is the only kidney disease that can be prevented
by a cheap drug, where secondary amyloidosis is
prevented by colchicine.
– FMF is nature’s experiment on inflammation and
understanding its pathogenesis teaches us about the
pathway of inflammation in other diseases as well.
– It is the most frequent autoinflammatory disease around
the world, reaching a frequency of 1/500–1/1,000 in
certain ethnic groups such as the Jewish, Turkish,
Armenian, and Arabic populations [39–41].
– And last but not least, FMF is associated with an
increased rate of vasculitic diseases that may affect the
kidney as well [8].
FMF is a monogenic autoinflammatory disease associ-
ated with mutations in a gene called MEFV (from
MEditerranean FeVer), identified more than 10 years ago.
The mutations in the MEFV gene are associated with
excess IL-1 production [42]. This results in clinical attacks
of inflammation in the form of fever and serositis in the
form of peritoneal, pleural, or synovial inflammation along
with increased acute-phase reactants. FMF patients may
have laboratory parameters of inflammation in between the
attacks as well with increased basal levels of erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), and
SAA [43]. This inflammatory state is what probably results
in the variety of problems related to clinical inflammation
observed in patients with FMF [8].
Pathophysiology The MEFV gene encodes a protein called
pyrin (from the Greek word for fever) [44]. This protein has
also been called marenostrin (from the Latin words mare
nostrum, the Mediterranean Sea) by the French Consortium
who simultaneously coded the gene, however, the former
name has been used more often [45]. FMF is basically
inherited in an autosomal recessive fashion. As stated
above, the carrier rate is very high in the Eastern
Mediterranean. In the past years we have studied the
possible causes of this high carrier rate, hypothesizing
that the carrier rate offered some advantage to the settlers
in the Eastern Mediterranean [46]. However, having
failed to blame a certain pathogen, we and others have
suggested that the carriers had the simple advantage of
mounting a better innate immune response to common
insults [47, 48].
Indeed mutations in pyrin result in increased inflamma-
tion through the innate immune system [42]. Pyrin is
localized in the cells of innate immunity; mainly the
neutrophils and the monocytes, and is an important element
of the inflammasome. Once a ‘danger’ signal is received,
the inflammasome assembles. This assembly activates
caspase leading to IL-1β production, resulting in high
basal levels of acute-phase reactants including the SAA
protein [38]. It is believed that persistently elevated SAA
reflecting ongoing inflammation plays the key role in the
development of amyloidosis (Fig. 2).
As the studies on mutations for FMF progressed, we
have become aware that there were patients with clear
phenotypes of the disease but who lacked mutations on
both alleles [38]. Recent studies have addressed this
problem, however, we lack definite answers to how patients
with one mutation only express the phenotype. Another
interesting aspect of this hereditary disease is the impact of
environment on the course and possibly the occurrence of
kidney complications [49, 50].
Clinical and laboratory features of FMF FMF is typically
characterized by recurrent attacks of fever and serositis
along with high acute-phase reactants. Onset of the
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patients [51]. In a multicenter study from Turkey,
representing the largest series of FMF, the mean ages of
onset and diagnosis were 9.6±8.6 years and 16.4±
11.6 years, respectively [11].
FMF attacks are typically accompanied by high fever
of 38.5–40.0°C. Recurrent attacks classically last 1/2–
3 days on average and resolve spontaneously. The
frequency of the cardinal signs and symptoms of FMF
are: fever (%92.5), peritonitis (% 93.7), arthritis (47.4%),
pleurisy ( 31.2%), amyloidosis (12.9%), and non-amyloid
glomerular disease (0.8%) [11]. Other signs and symptoms
such as headache, aseptic meningitis, pericarditis, spleno-
megaly, acute scrotum, and febrile myalgia scattered
purpura have also been reported [52, 53]. Symptoms may
not always be associated with attacks. For example,
erysipelas-like erythema and exertional myalgia of the
calves and feet are symptoms that are not always related
to the attacks [8].
Acute FMF attacks are associated with increases in ESR,
CRP, SAA, fibrinogen, and white blood cell count, which
return to lower levels after resolving of the symptoms.
Levels may remain above normal especially in untreated
patients and even carriers [54]. Every patient with FMF or
with periodic fever disease should have a work-up of
complete blood count, ESR, CRP, SAA if possible, and
urinalysis. If the child has not been treated properly and if
secondary amyloidosis develops, urinalysis will reveal
proteinuria [52]. If proteinuria is not diagnosed, it will
progress to full-blown nephrotic syndrome [8].
The differential diagnosis of the patient with FMF
includes all the other autoinflammatory diseases. These
diseases share the common phenotype of recurring inflam-
matory attacks but all have certain specific features. These
will also all be mentioned later in this review.
Factors affecting the development of amyloidosis in
FMF The frequency of amyloidosis in FMF patients is
not always associated with the frequency of attacks.
However, subclinical inflammation reflected with persis-
tently high SAA levels is considered to play a crucial role
in the deposition of amyloid fibrils in these patients. The
use of colchicine prevents the development of amyloidosis
[55]. Many studies have focused on the role of gender,
genetic, and environmental factors in the development of
amyloidosis in patients with FMF:
– Male gender and the presence of secondary amyloid-
osis in the family are significantly associated with the
development of amyloidosis [56].
– Although still controversial, many studies have indi-
cated that mutations in Exon 10, in the region between
680 and 694, and especially M694V homozygosity, are
associated with amyloidosis [11, 57, 58]. However,
patients with different mutations may also develop
amyloidosis [59].
– A number of polymorphisms related to the modifier
genes have been proposed as factors increasing the
development of amyloidosis: SAA1.1α/α genotype is
associated with a seven-times-higher risk of amyloid-
osis as compared to the other SAA genotypes and this
was confirmed in the Armenian, Jewish, and Turkish
populations [60, 61].
– Environment: As stated above, environment is believed
to affect the course of the disease. In their multicenter
multiethnic study, Toitou et al. [49] suggested that
country of recruitment was the key risk factor for renal
amyloidosis in FMF and they suggested that the
patient’s country should be considered along with
MEFV genotype as an indication for prophylactic
colchicine.
Other glomerular lesions in FMF Renal involvement other
than amyloidosis can be seen in FMF patients. In a
nationwide study enrolling 2,838 FMF patients from
Turkey, 22 had nonamyloid glomerular diseases [11].
Various types of glomerulonephritis have been reported in
this study [11]. Microscopic hematuria alone occurs in
fewer than 5% of FMF patients [51, 57]. Kidney biopsy is
probably not indicated if hematuria does not persist.
Vasculitis involving the kidney in FMF Certain rheumatic
diseases have an increased prevalence among patients with
FMF [53]. We initially noted in a small series that certain
vasculitides were increased among these patients. In the
aforementioned multicenter study from Turkey, polyarteritis
nodosa (PAN) (0.9%) and Henoch–Schönlein purpura
(HSP) (2.7%) indeed had a higher frequency, as expected
in the normal population [11]. Interestingly, in patients with
Fig. 2 The role of inflammasome in IL-1β production
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the overlap of microangiopathic polyangiitis (MPA) and
classic PAN, the younger age at onset, and better prognosis
[62].
Treatment in FMF Colchicine treatment has changed the
course of the disease by both reducing attack frequency and
severity and preventing amyloidosis. Goldinger first
described its effectiveness in 1972 and since then colchi-
cine became the drug of choice for FMF [63]. Colchicine,
an alkaloid, binds to β-tubulin hindering its polarization
with consequent defective transfer and mitosis, inhibition of
neutrophil chemotaxis, and reduced expression of adhesion
molecules [51]. Colchicine is mainly metabolized by the
liver. Colchicine is started at lower doses in children
(≤ 0.5 mg/day for children <5 years of age, 1.0 mg/day
for children 5–10 years of age and 1.5 mg/day for children
>10 years of age) compared to adults and the dose should
be monitored according to the clinical symptoms and SAA
levels [64]. Despite the narrow therapeutic index of the
drug, the recommended dose is safe, and side-effects are
minimal. The most frequent side-effect is diarrhea. Modi-
fication of diet, split doses, and dose reduction is
recommended for side-effects. Once symptoms resolve,
dosage should be increased in a stepwise fashion [64].
Resistance to colchicine is very rare [52]. If the diagnosis of
amyloidosis is established, colchicine dose should be
increased to 2 mg/day [64]. Colchicine treatment is the
mainstay against the prevention of amyloidosis [55].
Although colchicine treatment is not expected to dissolve
amyloid fibrils,ithas been shown thatcolchicinetherapy may
result in some stabilization or resolution of the proteinuric
stage [65, 66]. This may be due to the prevention of further
deposition in the renal tissue or the possible antifibrotic
effect of colchicine [67]. One of the most important
prognostic factors in amyloid nephropathy is interstitial
fibrosis [68]. In experimental settings, colchicine impairs
collagen synthesis and enhances collagenase activity [69].
Renal failure is associated with an increased risk of
colchicine toxicity [64, 66, 70, 71]. For patients with severe
renal failure (GFR <10 ml/min), the dosage should be
reduced by 50% [64, 72].
Cryopyrin-associated periodic syndromes
Cryopyrin-associated periodic syndromes (CAPS) are a
group of rare autoinflammatory diseases including familial
cold urticaria (FCAS), Muckle-Wells syndrome (MWS),
and chronic infantile neurologic cutaneous articular syn-
drome (CINCA), also known as neonatal onset multisystem
inflammatory disease (NOMID). They represent a continuum
ofseveritywithFCASbeingthemildestandNOMID/CINCA
being the most severe disease. CAPS are all caused by
mutations in CIAS1 encoding cryopyrin, which is a compo-
nent of the IL-1β inflammasome [38, 73, 74]. These are all
transmitted in an autosomal-dominant fashion.
Clinical and laboratory findings of CAPS Patients with
FCAS present with a history of cold-induced episodes of
inflammation that manifest with fever, urticaria-like rash,
joint pain, conjunctivitis, and headaches. The peak of the
attack occurs at 6–8 h and lasts up to 24 h. Amyloidosis is a
rare complication of FCAS (2–4%) [75].
In MWS, the typical attack includes fever, rash,
arthralgia, arthritis, myalgia, headaches, conjunctivitis,
episcleritis, and uveitis lasting up to 3 days. Progressive
sensorineural hearing loss develops in the second and
fourth decades. Amyloidosis develops in 25% of the cases
[73, 76].
The onset of CINCA-NOMID is at or within several
weeks of birth. It is characterized by urticaria-like rash,
fever, chronic aseptic meningitis, eye findings including
conjunctivitis, uveitis, and papillitis of the optic nerve. By
about 2 years, 50% of patients develop a severe arthropa-
thy. Patients have typical morphological changes of short
stature, frontal bossing, macrocephaly, saddle nose, short,
thick extremities with clubbing of fingers, and wrinkled
skin. If untreated, 20% die by age 20 years, and others
develop amyloidosis [74, 76].
Treatment in CAPS In FCAS and MWS, corticosteroids
may be used but are needed frequently and may cause
significant side-effects. Anti-IL-1 agents are very effective
in alleviating symptoms and decreasing inflammation in all
CAPS patients [76–78].
Hyperimmunoglobulinemia D and periodic fever syndrome
Hyperimmunoglobulinemia D syndrome (HIDS) is an
autosomal recessively inherited disease characterized by
fever, arthralgia, abdominal pain, diarrhea, maculopapular
rash, and lymphadenopathy lasting 3–7 days. The disease is
due to mutations in the mevalonate kinase gene [79].
Mutations in this pathway are associated with elevated IL1.
A number of treatments have been tried including bio-
logics. Secondary amyloidosis has been reported in 3% of
the patients, which is rarer than that reported for the other
monogenic autoinflammatory syndromes [43, 80].
Tumor necrosis factor receptor-associated
periodic syndrome
Tumor necrosis factor receptor-associated periodic syn-
drome (TRAPS) is an autosomal-dominant disorder char-
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arthritis, rash, and periorbital edema often lasting more
than 1 week [81]. When compared to FMF, attacks take
longer and eye and skin symptoms are more prominent
[82]. TRAPS has been reported in patients of many
ethnicities [83]. It is the second most common periodic
fever disorder with mutations in TNFRSF1A [81]. The 55-
kDa TNF receptor is widely expressed on cell membranes
and mediates proinflammatory action [84]. Patients with
TRAPS have an increased state of inflammation due to a
shedding defect in the TNF-alpha receptor or possibly due
to a misfolding disorder in the receptor [38].
Clinical attacks may include peritoneal inflammation or
pleurisy or both. Cutaneous symptoms consist of macular
areas or erythema, which is migratory in nature. Ocular
inflammation with per-orbital edema or conjunctivitis is
common. Arthralgia is more prominent than arthritis [82, 85].
Acute-phase reactants are increased during attacks and
may remain elevated in between clinical attacks. The
specific diagnosis is defined by mutations in TNFRSF1A
[81, 82]. Treatment depends on the severity of the disease.
For patients with infrequent attacks and normal SAA,
prednisone during attacks may be effective [82]. For
patients with more severe disease, etanercept or adalimu-
mab as anti-TNF agents were found to be effective [43, 82].
IL-1 receptor antagonist has also shown to be effective in
non-responsive patients [86]. Secondary amyloidosis is a
rather frequent complication especially in those who have
persistent inflammation despite treatment and affects 10%
of patients. The risk of amyloidosis appears to be greater
among patients with cysteine mutations [83].
Other autoinflammatory syndromes that may be associated
with secondary amyloidosis
The spectrum of autoinflammatory diseases has expanded
to include diseases with mutations in the innate immune
system pathway to polygenic/complex genetic trait dis-
eases. For example, in some patients with Crohn’s disease,
a mutation in NOD2, a molecule resembling cryopyrin, has
been identified [38]. On the other hand, Behçet’s disease is
now classified as a polygenic autoinflammatory disease due
to its specific features [53, 87, 88]. Both of these diseases
and more are known to be associated with secondary
amyloidosis in severe cases. The mechanism may be
speculated to be due to uncontrolled inflammation similar
to that in monogenic autoinflammatory diseases.
Rare causes of amyloidosis in childhood
Sickle cell anemia, chronic granulomatous disease-
associated aspergillosis, and Hodgkin's disease are other
diseases that have been very rarely associated with AA type
of amyloidosis in children in the medical literature [89–91].
AL-type amyloidosis
AL-typeamyloidosisisthemostcommontypeofamyloidosis
seen in adults. It is caused by deposition of protein derived
from immunoglobulin light-chain fragments. AL amyloidosis
is a plasma cell dyscrasia, which should be suspected with the
presence of a paraprotein in the serum or urine. Protein
immunoelectrophoresisandimmunofixationarenecessaryfor
the identification of monoclonal proteins. Since AL amyloid-
osis is a disease of the elderly, it will not be discussed further
here [1, 4, 92].
Treatment of amyloidosis
In general, amyloidosis has a poor prognosis if untreated
and undiagnosed. The prognosis is greatly influenced by
the type of amyloid protein involved and the extent of
organ involvement and damage. Therefore, the diagnosis of
amyloidosis and typing are crucial for the patient. In
practice, specific treatment of the underlying disorder,
aiming to suppress the inflammatory activity is the major
strategy. Treatment of amyloidosis will be discussed in
three sections: Targets and mechanisms of treatment,
specific treatment strategies for secondary amyloidosis,
and renal replacement therapy.
Targets of treatment Reducing the production of amyloido-
genic precursor protein (AA and AL amyloidosis) and
enhancing the clearance of amyloidogenic precursor protein
(Aβ2M amyloidosis) as well as trying to break down the
amyloid deposits are the aims of the therapy.
Colchicine is the prototype drug that decreases produc-
tion of amyloidogenic precursor protein. As stated above,
colchicine treatment is the mainstay against the prevention
of amyloidosis in FMF. Colchicine suppresses the inflam-
matory activity, decreases the severity and frequency of
attacks, and prevents amyloidosis in patients with FMF.
Clinical remission may occur at the stage of proteinuria in a
small number of FMF patients after colchicine treatment, as
discussed in the previous sections [55, 65, 66].
In the other autoinflammatory syndromes, specific
therapy for the suppression of inflammation is often
achieved with anti-IL1 treatment. Biologic treatment, such
as anti-TNF, anti-IL-1 therapy, may have a beneficial effect
on amyloidosis per se. However, many patients continue to
progress to end-stage renal failure, albeit with a longer renal
survival, even with these agents.
1222 Pediatr Nephrol (2011) 26:1215–1227In FMF patients developing secondary amyloidosis, most
centers would now also start using a biologic agent along
with colchicine in an attempt to effectively suppress
inflammation. There are reports suggesting the effective-
ness of anti-TNF and anti IL-1 antagonists on regression of
secondary amyloidosis [93–95]. Anti-IL-1 therapy has also
been tried in secondary amyloidosis in a patient with some
clinical response [96]. However, we await long-term studies
to understand whether these biologics prevent renal
insufficiency or simply prolong the process.
Specific treatment strategies for secondary amyloidosis New
treatment options directed to affect the amyloid structure
(e.g., diflunisal for hereditary amyloidosis) or to prevent
fibrillogenesis (e.g., eprodisate for AA amyloidosis) or to
weaken their structural stability (e.g., iododoxorubicin) are
being investigated, but current experience with these drugs
is limited [97–100].
Eprodisate is a member of a new class of compounds
designed to interfere with interactions between amyloido-
genic proteins and glycosaminoglycans and thereby inhibit
polymerization of amyloid fibrils and deposition of the fibrils
in tissues. A multicenter, randomized, placebo-controlled
study investigated the ability of eprodisate to prevent the
progression of AA amyloidosis-related nephropathy [99].
Eprodisate therapy slowed the progression of renal disease
compared to placebo. However, the drug had no significant
effect on progression to end-stage renal disease or risk of
death [99].
Renal replacement therapy Once end-stage renal disease
develops, patients can be treated with either dialysis or
renal transplantation [101–103]. Hemodialysis and perito-
neal dialysis (continuous ambulatory peritoneal dialysis or
automated peritoneal dialysis) appear to be equally effec-
tive, but some clinical manifestations complicate the
selection of dialysis type for an individual patient.
Unsuccessful vascular access due to vascular amyloid
infiltration, thrombosis of vascular access, and hypotension
make hemodialysis impossible in some patients. Peritoneal
dialysis is contraindicated in a patient with malnutrition and
hypoalbuminemia [104]. Colchicine should be continued in
dialysis patients who have FMF [64]. Renal transplantation
is one of the options, but the decision should be based on
other involved organs, especially the heart. Renal trans-
plantation, which can regress to amyloidosis, is the most
effective treatment in Aβ2M amyloidosis [105]. Combined
liver-kidney transplantation can prevent the recurrence of
amyloidosis in fibrinogen A alpha chain amyloidosis [106].
Delayed gastric emptying, drug interactions (e.g.,
cyclosporine-colchicine), and neuropathy (patients using
tacrolimus) can cause problems in renal transplant recipi-
ents [107, 108]. Treatment of colchicine-resistant FMF
patients with interferon could be challenging after renal
transplantation [109, 110]. The data regarding biological
treatments after renal transplantation is limited [111].
Other Symptomatic treatment is required for affected
organs. Angiotensin-converting enzyme inhibitors and
cholesterol-lowering statins may be added to the therapeutic
regimen.
Conclusions
The causes of secondary amyloidosis in children have been
changing over the years. In this decade, the autoinflamma-
tory diseases are the most common cause of reactive
amyloidosis in children. The nephrologist should be aware
that renal amyloidosis is potentially preventable in these
autoinflammatory diseases. Understanding the pathophysi-
ology of this group of diseases has not only improved our
understanding of inflammation and the innate immune
system but has also enabled us to better treat these diseases
and their complications as well.
Questions (answers appear following the reference list)
1. The main cause of childhood amyloidosis is
a. Juvenile idiopathic arthritis
b. Beta2 microglobulin amyloidosis
c. AFib amyloidosis
d. Familial Mediterranean fever
e. Familial cold autoinflammatory disease
2. Which one is wrong about the autoinflammatory
diseases causing secondary amyloidosis in children?
a. The mutations in the MEFV gene causing FMF are
associated with excess Il-6 production
b. Colchicine is the mainstay treatment for the
prevention of amyloidosis in FMF
c. CAPS is associated with mutations in cryopyrin
d. Hematuria may be seen in FMF
e. Secondary amyloidosis may occur in TRAPS
3. Which of the following is NOT associated with
secondary amyloidosis in FMF?
a. Male gender
b. Family history
c. SAA1.α/α genotype
d. Environment
e. E148Q homozygosity
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amyloidosis?
a. Colchicine is not effective in other causes of
secondary amyloidosis
b. Eprodisate weakens the structural stability of
amyloid fibrils
c. Hemodialysis and peritoneal dialysis appear to be
equally effective
d. Colchicine should be continued in dialysis patients
having FMF
e. Renal transplantation is the most effective treatment
in Aβ2M amyloidosis
5. What is the MOST common initial manifestation of
renal disease secondary to amyloidosis?
a. Hypertension
b. Asymptomatic hematuria
c. Asymptomatic proteinuria
d. Renal tubular acidosis
e. Chronic renal failure
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